American Heart Journal
Volume 146, Issue 2 , Pages 218-226 , August 2003

Endothelial dysfunction: clinical strategies for treating oxidant stress

  • Brett E Fenster, MD

      Affiliations

    • Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    • ,
  • Philip S Tsao, PhD

      Affiliations

    • Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    • ,
  • Stanley G Rockson, MD

      Affiliations

    • Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    • Corresponding Author InformationReprint requests: Stanley G. Rockson, MD, Division of Cardiovascular Medicine, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA 94305, USA.

Received 26 February 2002 ,Accepted 15 August 2002.

References 

  1. Irani K. Oxidant signaling in vascular cell growth, death, and survival (a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling). Circ Res. 2000;87:179–183
  2. Griendling KK, Minieri CA, Ollerenshaw JD, et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–1148
  3. Rajagopalan S, Kurz S, Munzel T, et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation (contribution to alterations of vasomotor tone). J Clin Invest. 1996;97:1916–1923
  4. Laursen JB, Rajagopalan S, Galis Z, et al.  Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:588–593
  5. Guzik TJ, West NE, Black E, et al.  Vascular superoxide production by NAD(P)H oxidase (association with endothelial dysfunction and clinical risk factors). Circ Res. 2000;86:E85–90
  6. Azumi H, Inoue N, Takeshita S, et al.  Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation. 1999;100:1494–1498
  7. Cahilly C, Ballantyne CM, Lim DS, et al.  A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res. 2000;86:391–395
  8. Heitzer T, Brockhoff C, Mayer B, et al.  Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers (evidence for a dysfunctional nitric oxide synthase). Circ Res. 2000;86:E36–41
  9. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol. 1997;29:8–15
  10. Adams MR, McCredie R, Jessup W, et al.  Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis. 1997;129:261–269
  11. Boger RH, Bode-Boger SM, Szuba A, et al.  Asymmetric dimethylarginine (ADMA) (a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia). Circulation. 1998;98:1842–1847
  12. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol. 1997;80:331–333
  13. Boger RH, Bode-Boger SM, Thiele W, et al.  Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol. 1998;32:1336–1344
  14. Mervaala EM, Cheng ZJ, Tikkanen I, et al.  Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension. 2001;37:414–418
  15. Cardillo C, Kilcoyne CM, Cannon RO, et al.  Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 1997;30:57–63
  16. Butler R, Morris AD, Belch JJ, et al.  Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35:746–751
  17. Ting HH, Timimi FK, Boles KS, et al.  Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996;97:22–28
  18. Motoyama T, Kawano H, Kugiyama K, et al.  Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. J Am Coll Cardiol. 1998;32:1672–1679
  19. Elliott TG, Barth JD, Mancini GB. Effects of vitamin E on endothelial function in men after myocardial infarction. Am J Cardiol. 1995;76:1188–1190
  20. Stephens NG, Parsons A, Schofield PM, et al.  Randomised controlled trial of vitamin E in patients with coronary disease (Cambridge Heart Antioxidant Study (CHAOS)). Lancet. 1996;347:781–786
  21. Yusuf S, Dagenais G, Pogue J, et al.  Vitamin E supplementation and cardiovascular events in high-risk patients (the Heart Outcomes Prevention Evaluation Study Investigators). N Engl J Med. 2000;342:154–160
  22. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico . Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction (results of the GISSI-Prevenzione trial). Lancet. 1999;354:447–455
  23. Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein (when and how this antioxidant becomes a pro-oxidant). Biochem J. 1992;288:341–344
  24. Hernandez-Presa M, Bustos C, Ortego M, et al.  Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532–1541
  25. Wang HD, Xu S, Johns DG, et al.  Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001;88:947–953
  26. Dzau VJ. Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease (a unifying hypothesis). Hypertension. 2001;37:1047–1052
  27. Mancini GB, Henry GC, Macaya C, et al.  Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease (the TREND (Trial on Reversing ENdothelial Dysfunction) Study). Circulation. 1996;94:258–265
  28. Anderson TJ, Elstein E, Haber H, et al.  Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000;35:60–66
  29. Yusuf S, Sleight P, Pogue J, et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (the Heart Outcomes Prevention Evaluation Study Investigators). N Engl J Med. 2000;342:145–153
  30. Anderson TJ, Elstein E, Haber H, et al.  Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000;35:60–66
  31. Treasure CB, Klein JL, Weintraub WS, et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481–487
  32. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126–1131
  33. Di-Poi N, Faure J, Grizot S, et al.  Mechanism of NADPH oxidase activation by the Rac/Rho-GDI complex. Biochemistry. 2001;40:10014–10022
  34. Kandabashi T, Shimokawa H, Miyata K, et al.  Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1 beta. Circulation. 2000;101:1319–1323
  35. Hernandez-Perera O, Perez-Sala D, Soria E, et al.  Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res. 2000;87:616–622
  36. Wilson SH, Simari RD, Best PJ, et al.  Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol. 2001;21:122–128
  37. Wassmann S, Laufs U, Baumer AT, et al.  HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:1450–1457
  38. De Mattia G, Bravi MC, Laurenti O, et al.  Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia. 1998;41:1392–1396
  39. Watanabe Y, Sunayama S, Shimada K, et al.  Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb. 2000;7:159–163
  40. Murakami T, Mizuno S, Ohsato K, et al.  Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol. 1999;84:92–94 , A8
  41. Avena R, Mitchell ME, Nylen ES, et al.  Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg. 1998;28:1024–1032
  42. Garg R, Kumbkarni Y, Aljada A, et al.  Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension. 2000;36:430–435
  43. Aljada A, Garg R, Ghanim H, et al.  Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes (evidence of an antiinflammatory action?). J Clin Endocrinol Metab. 2001;86:3250–3256
  44. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344–1350
  45. Kanani PM, Sinkey CA, Browning RL, et al.  Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999;100:1161–1168
  46. Raghuveer G, Sinkey CA, Chenard C, et al.  Effect of vitamin E on resistance vessel endothelial dysfunction induced by methionine. Am J Cardiol. 2001;88:285–290
  47. Thambyrajah J, Landray MJ, Jones HJ, et al.  A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol. 2001;37:1858–1863
  48. Lieberman EH, Gerhard MD, Uehata A, et al.  Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936–941
  49. Hulley S, Grady D, Bush T, et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613
  50. Brown BG, Zhao XQ, Chait A, et al.  Simvastatin and niacin, anti-oxidant vitamins, for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592

PII: S0002-8703(02)94796-4

doi: 10.1016/S0002-8703(02)94796-4

American Heart Journal
Volume 146, Issue 2 , Pages 218-226 , August 2003

Article Tools

* Image Usage & Resolution